Researchers said the heart remains scarred and natural regrowth is insufficient, but the discovery could help develop regenerative therapies to repair damage and treat heart failure.
Cardiovascular disease causes 24% of deaths in Australia; heart attacks can kill up to one-third of heart cells, while about 144,000 Australians live with heart failure and only 115 transplants occur yearly.
Could this discovery mean a future where heart transplants are no longer needed, or are there hidden risks that could slow clinical use?
Will enhancing heart regeneration create new dangers, like cancer or arrhythmias, and how will doctors manage these risks in future treatments?
With the heart’s hidden regenerative ability now proven, how close are we to real therapies—and what obstacles remain before patients benefit?
First Confirmation of 7-11% Cardiomyocyte Regeneration in Adult Human Hearts: Pathways and Therapeutic Advances
Overview
In early 2026, researchers from the University of Sydney and partners discovered that 7-11% of adult human heart muscle cells can regenerate after a heart attack, overturning the long-held belief that the heart cannot repair itself. They identified key pathways, CLIPPER-LPIN1 and RBM22-SMARCA4, that control this limited regeneration by regulating metabolism and gene activation. Despite this potential, challenges like immune rejection, arrhythmia risks, and manufacturing hurdles remain. Japan’s conditional approval of iPSC-based heart therapies marks a milestone, while ongoing trials and research aim to enhance these therapies. Successful heart regeneration could revolutionize treatment, reducing reliance on transplants and improving patient outcomes worldwide.